545 related articles for article (PubMed ID: 32896428)
1. Systemic therapy for metastatic HER2-positive breast cancer.
Bredin P; Walshe JM; Denduluri N
Semin Oncol; 2020 Oct; 47(5):259-269. PubMed ID: 32896428
[TBL] [Abstract][Full Text] [Related]
2. Developments in the Management of Metastatic HER2-Positive Breast Cancer: A Review.
Lebert J; Lilly EJ
Curr Oncol; 2022 Apr; 29(4):2539-2549. PubMed ID: 35448182
[TBL] [Abstract][Full Text] [Related]
3. Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer.
Murthy RK; Loi S; Okines A; Paplomata E; Hamilton E; Hurvitz SA; Lin NU; Borges V; Abramson V; Anders C; Bedard PL; Oliveira M; Jakobsen E; Bachelot T; Shachar SS; Müller V; Braga S; Duhoux FP; Greil R; Cameron D; Carey LA; Curigliano G; Gelmon K; Hortobagyi G; Krop I; Loibl S; Pegram M; Slamon D; Palanca-Wessels MC; Walker L; Feng W; Winer EP
N Engl J Med; 2020 Feb; 382(7):597-609. PubMed ID: 31825569
[TBL] [Abstract][Full Text] [Related]
4. Metastatic HER2-Positive Breast Cancer: Is There an Optimal Sequence of Therapy?
Dempsey N; Sandoval A; Mahtani R
Curr Treat Options Oncol; 2023 Sep; 24(9):1120-1137. PubMed ID: 37428332
[TBL] [Abstract][Full Text] [Related]
5. Tucatinib with capecitabine and trastuzumab in advanced HER2-positive metastatic breast cancer with and without brain metastases: a non-randomised, open-label, phase 1b study.
Murthy R; Borges VF; Conlin A; Chaves J; Chamberlain M; Gray T; Vo A; Hamilton E
Lancet Oncol; 2018 Jul; 19(7):880-888. PubMed ID: 29804905
[TBL] [Abstract][Full Text] [Related]
6. Novel HER2-targeted therapies for HER2-positive metastatic breast cancer.
Kunte S; Abraham J; Montero AJ
Cancer; 2020 Oct; 126(19):4278-4288. PubMed ID: 32721042
[TBL] [Abstract][Full Text] [Related]
7. Tucatinib Combined With Ado-Trastuzumab Emtansine in Advanced ERBB2/HER2-Positive Metastatic Breast Cancer: A Phase 1b Clinical Trial.
Borges VF; Ferrario C; Aucoin N; Falkson C; Khan Q; Krop I; Welch S; Conlin A; Chaves J; Bedard PL; Chamberlain M; Gray T; Vo A; Hamilton E
JAMA Oncol; 2018 Sep; 4(9):1214-1220. PubMed ID: 29955792
[TBL] [Abstract][Full Text] [Related]
8. HER2-positive metastatic breast cancer: a comprehensive review.
Exman P; Tolaney SM
Clin Adv Hematol Oncol; 2021 Jan; 19(1):40-50. PubMed ID: 33493147
[TBL] [Abstract][Full Text] [Related]
9. Current treatment options for HER2-positive breast cancer patients with brain metastases.
Galanti D; Inno A; La Vecchia M; Borsellino N; Incorvaia L; Russo A; Gori S
Crit Rev Oncol Hematol; 2021 May; 161():103329. PubMed ID: 33862249
[TBL] [Abstract][Full Text] [Related]
10. Neoadjuvant trastuzumab, pertuzumab, and chemotherapy versus trastuzumab emtansine plus pertuzumab in patients with HER2-positive breast cancer (KRISTINE): a randomised, open-label, multicentre, phase 3 trial.
Hurvitz SA; Martin M; Symmans WF; Jung KH; Huang CS; Thompson AM; Harbeck N; Valero V; Stroyakovskiy D; Wildiers H; Campone M; Boileau JF; Beckmann MW; Afenjar K; Fresco R; Helms HJ; Xu J; Lin YG; Sparano J; Slamon D
Lancet Oncol; 2018 Jan; 19(1):115-126. PubMed ID: 29175149
[TBL] [Abstract][Full Text] [Related]
11. Targeting HER2 in Breast Cancer: Latest Developments on Treatment Sequencing and the Introduction of Biosimilars.
Tesch ME; Gelmon KA
Drugs; 2020 Nov; 80(17):1811-1830. PubMed ID: 33021725
[TBL] [Abstract][Full Text] [Related]
12. Metastatic Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Current Treatment Standards and Future Perspectives.
Dormann C
Breast Care (Basel); 2020 Dec; 15(6):570-578. PubMed ID: 33447230
[TBL] [Abstract][Full Text] [Related]
13. Neratinib: an option for HER2-positive metastatic breast cancer.
O'Shaughnessy JA; O'Regan R; Isaacs C
Clin Adv Hematol Oncol; 2020 Sep; 18 Suppl 15(9):1-20. PubMed ID: 33843838
[TBL] [Abstract][Full Text] [Related]
14. Therapeutic landscape of advanced HER2-positive breast cancer in 2022.
Gupta R; Gupta S; Antonios B; Ghimire B; Jindal V; Deol J; Gaikazian S; Huben M; Anderson J; Stender M; Jaiyesimi I
Med Oncol; 2022 Oct; 39(12):258. PubMed ID: 36224475
[TBL] [Abstract][Full Text] [Related]
15. Trastuzumab emtansine with or without pertuzumab versus trastuzumab with taxane for human epidermal growth factor receptor 2-positive advanced breast cancer: Final results from MARIANNE.
Perez EA; Barrios C; Eiermann W; Toi M; Im YH; Conte P; Martin M; Pienkowski T; Pivot XB; Burris HA; Petersen JA; De Haas S; Hoersch S; Patre M; Ellis PA
Cancer; 2019 Nov; 125(22):3974-3984. PubMed ID: 31318460
[TBL] [Abstract][Full Text] [Related]
16. Optimal treatment of early stage HER2-positive breast cancer.
Pernas S; Barroso-Sousa R; Tolaney SM
Cancer; 2018 Dec; 124(23):4455-4466. PubMed ID: 30291791
[TBL] [Abstract][Full Text] [Related]
17. [Therapeutic advances in HER2+ breast cancer].
Alexandre M; Jacot W
Rev Prat; 2023 Apr; 73(4):355-359. PubMed ID: 37289145
[TBL] [Abstract][Full Text] [Related]
18. Pertuzumab for the treatment of human epidermal growth factor receptor type 2-positive metastatic breast cancer.
Chung C; Lam MS
Am J Health Syst Pharm; 2013 Sep; 70(18):1579-87. PubMed ID: 23988598
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of late line pertuzumab with trastuzumab and chemotherapy in HER2-positive metastatic breast cancer: An Australian case series.
Bergin ART; Luen SJ; Savas P; Boolell V; Cho D; Lynch J; Nott L; Stuart-Harris R; Teo LN; Yap SY; Loi S
Asia Pac J Clin Oncol; 2019 Dec; 15(6):377-382. PubMed ID: 31321873
[TBL] [Abstract][Full Text] [Related]
20. Pertuzumab and trastuzumab with or without metronomic chemotherapy for older patients with HER2-positive metastatic breast cancer (EORTC 75111-10114): an open-label, randomised, phase 2 trial from the Elderly Task Force/Breast Cancer Group.
Wildiers H; Tryfonidis K; Dal Lago L; Vuylsteke P; Curigliano G; Waters S; Brouwers B; Altintas S; Touati N; Cardoso F; Brain E
Lancet Oncol; 2018 Mar; 19(3):323-336. PubMed ID: 29433963
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
